Chicago Partners Investment Group LLC Invests $367,000 in BioMarin Pharmaceutical Inc. $BMRN

Chicago Partners Investment Group LLC purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,144 shares of the biotechnology company’s stock, valued at approximately $367,000.

Several other institutional investors and hedge funds also recently modified their holdings of BMRN. Nuveen LLC bought a new position in shares of BioMarin Pharmaceutical in the first quarter worth $184,475,000. AQR Capital Management LLC boosted its stake in BioMarin Pharmaceutical by 127.9% during the first quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock valued at $203,987,000 after buying an additional 1,642,206 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in BioMarin Pharmaceutical by 212.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock valued at $112,607,000 after buying an additional 1,083,512 shares in the last quarter. Fuller & Thaler Asset Management Inc. bought a new position in BioMarin Pharmaceutical during the first quarter valued at about $59,125,000. Finally, Robeco Institutional Asset Management B.V. boosted its stake in BioMarin Pharmaceutical by 559.8% during the second quarter. Robeco Institutional Asset Management B.V. now owns 641,718 shares of the biotechnology company’s stock valued at $35,275,000 after buying an additional 544,457 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Trading Up 2.2%

NASDAQ:BMRN opened at $54.55 on Friday. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a 1-year low of $51.56 and a 1-year high of $73.51. The firm has a market capitalization of $10.47 billion, a price-to-earnings ratio of 16.19, a price-to-earnings-growth ratio of 0.67 and a beta of 0.33. The stock has a fifty day simple moving average of $55.35 and a 200 day simple moving average of $57.29.

Analysts Set New Price Targets

Several research analysts recently weighed in on BMRN shares. HC Wainwright started coverage on BioMarin Pharmaceutical in a research note on Monday, September 8th. They set a “neutral” rating and a $60.00 target price for the company. UBS Group raised their target price on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Wolfe Research set a $95.00 target price on BioMarin Pharmaceutical and gave the company an “outperform” rating in a research note on Tuesday, July 15th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, October 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $93.26.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.